37 related articles for article (PubMed ID: 19602718)
1. Population Pharmacokinetic Modeling and Simulation of Pudexacianinium (ASP5354) for Dose Setting of a Phase 2 First-in-Patient Study: A Novel Imaging Agent for Intraoperative Ureter Visualization during Abdominopelvic Surgery.
Saito M; Kojima T; Komatsu K; Takusagawa S
Clin Pharmacol Drug Dev; 2024 May; 13(5):454-464. PubMed ID: 38135485
[TBL] [Abstract][Full Text] [Related]
2. Advancements in Polymeric Nanocarriers to Mediate Targeted Therapy against Triple-Negative Breast Cancer.
Fatima M; Sheikh A; Abourehab MAS; Kesharwani P
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36365249
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Pharmacokinetic Profiles of Trientine Tetrahydrochloride and Trientine Dihydrochloride in Healthy Subjects.
Weiss KH; Thompson C; Dogterom P; Chiou YJ; Morley T; Jackson B; Amin N; Kamlin COF
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):665-675. PubMed ID: 34357516
[TBL] [Abstract][Full Text] [Related]
4. A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy.
Huang YF; Kuo MT; Liu YS; Cheng YM; Wu PY; Chou CY
Front Oncol; 2019; 9():437. PubMed ID: 31179244
[No Abstract] [Full Text] [Related]
5. Trientine selectively delivers copper to the heart and suppresses pressure overload-induced cardiac hypertrophy in rats.
Liu J; Chen C; Liu Y; Sun X; Ding X; Qiu L; Han P; James Kang Y
Exp Biol Med (Maywood); 2018 Oct; 243(14):1141-1152. PubMed ID: 30472883
[TBL] [Abstract][Full Text] [Related]
6. The steady state pharmacokinetics of trientine in Wilson disease patients.
Pfeiffenberger J; Kruse C; Mutch P; Harker A; Weiss KH
Eur J Clin Pharmacol; 2018 Jun; 74(6):731-736. PubMed ID: 29417175
[TBL] [Abstract][Full Text] [Related]
7. Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation.
Zhang S; Liu H; Amarsingh GV; Cheung CC; Hogl S; Narayanan U; Zhang L; McHarg S; Xu J; Gong D; Kennedy J; Barry B; Choong YS; Phillips AR; Cooper GJ
Cardiovasc Diabetol; 2014 Jun; 13():100. PubMed ID: 24927960
[TBL] [Abstract][Full Text] [Related]
8. Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats.
Zhang L; Ward ML; Phillips AR; Zhang S; Kennedy J; Barry B; Cannell MB; Cooper GJ
Cardiovasc Diabetol; 2013 Aug; 12():123. PubMed ID: 23981320
[TBL] [Abstract][Full Text] [Related]
9. Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairment.
Lu J; Pontré B; Pickup S; Choong SY; Li M; Xu H; Gamble GD; Phillips AR; Cowan BR; Young AA; Cooper GJ
Cardiovasc Diabetol; 2013 Jan; 12():28. PubMed ID: 23368770
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Li J; Jameson MB; Baguley BC; Pili R; Baker SD
Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.
Cooper GJ
Drugs; 2011 Jul; 71(10):1281-320. PubMed ID: 21770477
[TBL] [Abstract][Full Text] [Related]
12. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic modeling of a copper-selective chelator (TETA) in healthy adults.
Cho HY; Blum RA; Sunderland T; Cooper GJ; Jusko WJ
J Clin Pharmacol; 2009 Aug; 49(8):916-28. PubMed ID: 19602718
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial.
Lu J; Poppitt SD; Othman AA; Sunderland T; Ruggiero K; Willett MS; Diamond LE; Garcia WD; Roesch BG; Cooper GJ
J Clin Pharmacol; 2010 Jun; 50(6):647-58. PubMed ID: 20145262
[TBL] [Abstract][Full Text] [Related]
15. Triethylenetetramine and metabolites: levels in relation to copper and zinc excretion in urine of healthy volunteers and type 2 diabetic patients.
Lu J; Chan YK; Gamble GD; Poppitt SD; Othman AA; Cooper GJ
Drug Metab Dispos; 2007 Feb; 35(2):221-7. PubMed ID: 17108057
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
